JP2010540674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540674A5 JP2010540674A5 JP2010528318A JP2010528318A JP2010540674A5 JP 2010540674 A5 JP2010540674 A5 JP 2010540674A5 JP 2010528318 A JP2010528318 A JP 2010528318A JP 2010528318 A JP2010528318 A JP 2010528318A JP 2010540674 A5 JP2010540674 A5 JP 2010540674A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- recombinant
- peptide
- expression
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97853607P | 2007-10-09 | 2007-10-09 | |
| PCT/EP2008/008544 WO2009046984A1 (en) | 2007-10-09 | 2008-10-09 | Hiv preventive vaccine based on hiv specific antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010540674A JP2010540674A (ja) | 2010-12-24 |
| JP2010540674A5 true JP2010540674A5 (https=) | 2013-10-03 |
Family
ID=40342551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528318A Pending JP2010540674A (ja) | 2007-10-09 | 2008-10-09 | Ｈｉｖ特異抗体に基づくｈｉｖ予防ワクチン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100215695A1 (https=) |
| EP (1) | EP2205736B1 (https=) |
| JP (1) | JP2010540674A (https=) |
| KR (1) | KR20100098597A (https=) |
| CN (1) | CN101970659A (https=) |
| AU (1) | AU2008309940B2 (https=) |
| BR (1) | BRPI0818354A2 (https=) |
| CA (1) | CA2701948A1 (https=) |
| MX (1) | MX2010003762A (https=) |
| RU (1) | RU2505604C2 (https=) |
| WO (1) | WO2009046984A1 (https=) |
| ZA (1) | ZA201002445B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2422618A1 (en) * | 2010-08-27 | 2012-02-29 | Technologie Integrale Ltd. | Animal model for the evaluation of the efficacy of an HIV vaccine |
| CN102190726B (zh) * | 2011-03-30 | 2013-03-27 | 中国医学科学院病原生物学研究所 | 一种人源HIV抗体的Fab片段及其编码基因与应用 |
| CN102212133B (zh) * | 2011-03-30 | 2013-01-16 | 中国医学科学院病原生物学研究所 | 人源HIV抗体的Fab片段及其编码基因与应用 |
| HK1200359A1 (zh) * | 2011-09-17 | 2015-08-07 | 源道隆（苏州）医学科技有限公司 | 任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导 |
| US10660951B2 (en) | 2012-09-17 | 2020-05-26 | Zhiwei Allen Wu | Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof |
| EP2745845A1 (en) * | 2012-12-19 | 2014-06-25 | Centre Hospitalier Universitaire de Bordeaux | A method for preventing or treating an HIV infection |
| PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| RU2600031C2 (ru) * | 2014-11-11 | 2016-10-20 | Публичное акционерное общество "Фармсинтез" | Лекарственная форма специфического иммунобиологического лекарственного средства для лечения и профилактики вич инфекции и способ ее получения |
| EP3464348A4 (en) * | 2016-05-25 | 2020-01-22 | University Of Maryland, Baltimore | METHOD FOR PRODUCING ACTIVE ANTIBODIES FROM BIOLOGICAL LIQUIDS |
| CN106800603B (zh) * | 2017-01-24 | 2020-07-28 | 中国食品药品检定研究院 | 检测抗hiv抗体的adcc活性的方法 |
| US20200172601A1 (en) | 2017-06-22 | 2020-06-04 | University Of Maryland, Baltimore | Broadly neutralizing antibodies against hiv |
| IT202100004160A1 (it) * | 2021-02-23 | 2022-08-23 | Univ Degli Studi Milano | Cellula ospite di leishmania |
| IT202100004172A1 (it) * | 2021-02-23 | 2022-08-23 | Univ Degli Studi Milano | Nuova composizione |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2237065C2 (ru) * | 2002-10-03 | 2004-09-27 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека |
| US20040109876A1 (en) * | 2002-11-25 | 2004-06-10 | Kureha Chemical Industry Co., Ltd. | Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV |
-
2008
- 2008-10-09 CN CN2008801156626A patent/CN101970659A/zh active Pending
- 2008-10-09 JP JP2010528318A patent/JP2010540674A/ja active Pending
- 2008-10-09 EP EP08802850.1A patent/EP2205736B1/en not_active Not-in-force
- 2008-10-09 KR KR1020107009984A patent/KR20100098597A/ko not_active Ceased
- 2008-10-09 BR BRPI0818354A patent/BRPI0818354A2/pt not_active IP Right Cessation
- 2008-10-09 RU RU2010116849/10A patent/RU2505604C2/ru not_active IP Right Cessation
- 2008-10-09 CA CA2701948A patent/CA2701948A1/en not_active Abandoned
- 2008-10-09 US US12/526,038 patent/US20100215695A1/en not_active Abandoned
- 2008-10-09 AU AU2008309940A patent/AU2008309940B2/en not_active Ceased
- 2008-10-09 MX MX2010003762A patent/MX2010003762A/es active IP Right Grant
- 2008-10-09 WO PCT/EP2008/008544 patent/WO2009046984A1/en not_active Ceased
-
2010
- 2010-04-07 ZA ZA2010/02445A patent/ZA201002445B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540674A5 (https=) | ||
| Zhang et al. | A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques | |
| JP6942309B2 (ja) | フラビウイルスウイルス様粒子 | |
| EP1780285A1 (en) | Improved virus like particles (VLP) based on the small envelope protein of hepatitis B virus (HBsAg-S) | |
| Jiang et al. | Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy | |
| SG175781A1 (en) | Recombinant virus-like particles encoded by multi-gene vector | |
| AU2018358238A1 (en) | Novel scaffolded HIV-1 vaccine immunogens | |
| JP2014513956A (ja) | 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物 | |
| Gonelli et al. | Immunogenicity of HIV-1-based virus-like particles with increased incorporation and stability of membrane-bound Env | |
| WO2022162012A2 (en) | Antibodies broadly targeting coronaviruses and uses thereof | |
| He et al. | Self-assembling nanoparticles presenting receptor binding domain and stabilized spike as next-generation COVID-19 vaccines | |
| CN114213509B (zh) | 基于SARS-CoV-2的S蛋白的疫苗及其用途 | |
| Eslamizar et al. | Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center | |
| US8017126B2 (en) | Modified HIV-1 envelope proteins | |
| US7608277B2 (en) | Tuberculosis nucleic acids, polypeptides and immunogenic compositions | |
| KR20230156945A (ko) | 백신 조성물 및 이의 사용 방법 | |
| US20120039923A1 (en) | Modified HIV-1 Envelope Proteins | |
| US20060222658A1 (en) | Vaccinia virus nucleic acids, polypeptides and immunogenic compositions | |
| RU2848314C1 (ru) | Профилактика и лечение бетакоронавируса | |
| Raman et al. | The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1 | |
| EP3104884B1 (en) | A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection | |
| WO2022161598A1 (en) | Antibodies broadly targeting coronaviruses and uses thereof |